ToolGen, Inc. , a Korean biotechnology company with a focus in the genome editing space, and Thermo Fisher Scientific, the world leader in serving science, announced an agreement under which ToolGen, Inc. will license its CRISPR/Cas9 intellectual property portfolio to Thermo Fisher Scientific.
Under the terms of the agreement, Thermo Fisher Scientific is granted a worldwide license for research applications including the development and sale of reagents, cell lines, and animal models, as well as rights for high throughput screening, diagnostics, and bioproduction.
Thermo Fisher aims to develop new CRISPr reagent kits, to enable researchers working in this rapidly growing field. It already has a strong presence in this field, with a kit for the complementary Transcription activator-like effector nucleases (TALEN) technique. The licensed intellectual property for this technology is based, in part, on the discovery by Dr. Jin Soo Kim, a researcher at Seoul National University and co-founder of ToolGen, Inc., that the CRISPR/Cas9 system can be used to engineer these cells found in multicellular organisms such as mammals, plants and fungi.
CRISPR/Cas9 system, which was originally identified as part of the adaptive immune system of many bacterial species, is used by scientists for targeted genome engineering in eukaryotic cells. It has the power to perform targeted, highly efficient alterations of genome sequence and gene expression and have the ability to transform biological research and spur the development of novel molecular therapeutics for various diseases.